Martin M. Eatock

Lisburn Road
Belfast, NIR, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.

Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.

Journal: BMJ open

Published: February 06, 2025

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Journal: ESMO open

Published: May 23, 2024

Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series.

Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series.

Journal: BMC sports science, medicine & rehabilitation

Published: April 17, 2023

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma.

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma.

Journal: Scientific reports

Published: December 08, 2020

Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic".

Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic".

Journal: British journal of cancer

Published: September 08, 2020

Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review.

Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review.

Journal: BMC cancer

Published: July 24, 2020

Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position.

Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position.

Journal: British journal of cancer

Published: April 14, 2020

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 22, 2019

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Journal: Gut

Published: September 19, 2018

Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.

Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.

Journal: Journal of comparative effectiveness research

Published: September 01, 2018

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Journal: Oncotarget

Published: December 19, 2017

Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.

Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.

Journal: Annals of clinical biochemistry

Published: September 18, 2016

Showing 1-12 of 21

Last Updated: 09/26/2026